Nuvalent

Edit info

Founded: 2017

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: NSCLC

Drug types: ONC

Lead product: NVL-520

Funding: $230M stock Oct 2022; $190M IPO Jul 2021; $135M B May 2021; $50M A Jan 2021

nuvalent.com

linkedin.com

job board

Drug notes:

NVL-655 Clin1 NSCLC; NVL-330 Clin0 NSCLC; undisclosed RD NSCLC

About:

Nuvalent is using structure-based drug discovery to create precision medicines for cancer patients. Kinase inhibitors have driven the target therapy revolution in oncology, however, clinical utility is limited by the kinase resistance and selectivity problems. The former is caused by cancer mutations in kinases that become resistant to inhibitors and the latter is due to the similar structural drug binding site of different kinases causing off-target effects. Nuvalent is overcoming the challenges of resistance and selectivity by using structure-based design with clinical insight to find small molecules that inhibit clinically proven kinase targets. Nuvalent’s most advanced drug, NVL-520, targets the kinase ROS1 and is being investigated for patients with non-small cell lung cancer.